NASDAQ:NRIX Nurix Therapeutics Q3 2024 Earnings Report $9.80 -0.02 (-0.20%) As of 04:00 PM Eastern Earnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPS-$0.67Consensus EPS -$0.67Beat/MissMet ExpectationsOne Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual Revenue$12.59 millionExpected Revenue$13.85 millionBeat/MissMissed by -$1.26 millionYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ3 2024Date10/11/2024TimeAfter Market ClosesConference Call DateFriday, October 11, 2024Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Remove Ads Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nurix Therapeutics Earnings HeadlinesWells Fargo & Company Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $25.00April 12, 2025 | americanbankingnews.comQ2 EPS Forecast for Nurix Therapeutics Increased by AnalystApril 12, 2025 | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 16, 2025 | Paradigm Press (Ad)Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comStifel Nicolaus Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $35.00April 11, 2025 | americanbankingnews.comNurix Therapeutics price target lowered to $25 from $32 at Wells FargoApril 10, 2025 | markets.businessinsider.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX), a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s Next Upcoming Earnings Netflix (4/17/2025)American Express (4/17/2025)Blackstone (4/17/2025)Infosys (4/17/2025)Marsh & McLennan Companies (4/17/2025)Charles Schwab (4/17/2025)Taiwan Semiconductor Manufacturing (4/17/2025)UnitedHealth Group (4/17/2025)HDFC Bank (4/18/2025)Intuitive Surgical (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
